KUALA LUMPUR, July 15 (Bernama) -- Haemonetics Corporation's investment in Malaysia will boost efficiencies in blood management practices globally, says Biotechnology Corporation Sdn Bhd (BiotechCorp) chief executive officer, Datuk Dr Mohd Nazlee Kamal.
It will also he said, add technical value to the Malaysian economy.
Haemonetics is a global leader in blood management and the investment in Malaysia is also the company's first of its kind in South East Asia.
Haemonetics has chosen to construct its world-class facility for manufacturing Whole Blood and Apheresis devices in Penang, as Malaysia offers firm proximity to customers in its fastest growing markets, as well as a number of key suppliers and medical equipment manufacturers.
Among the benefits to the Malaysian economy is acquisition of new blood management and medical technologies, a huge equipment and localisation investment, as well as investments in capital.
It also offers job creation for locals, alongside extensive training and development for them.
"Malaysia is now at a transformational stage where we are able to attract Medical Device investments of high-end manufacturing with innovative technologies.
"BiotechCorp as the leading government agency tasked with supporting the biotechnology industry in Malaysia, is also responsible for the development of a viable ecosystem in Malaysia to support research and development, and commercial biotechnology ventures.
"In this case, we have been working very closely with the Malaysian Investment Development Authority and InvestPenang, to make the Haemonetics investment a reality," said Mohd Nazlee in a statement today.
Haemonetics recently announced several important developments, including a plan to cease production operations at its Italian manufacturing facility, selection of Sanmina Corporation for equipment contract manufacturing and the Malaysian location for its Asian manufacturing site, in the pursuit of a previously announced manufacturing transformation
Its executive vice president of Global Manufacturing, David Helsel said much of the company's revenue growth was derived from emerging markets, and thus the selection of Penang for the manufacturing site.
"It also makes for much leaner, more efficient operations," he added.
Meanwhile, Sudhakar Varshney, Haemonetics' vice president of Global Engineering said Penang offered good infrastructure, a well-established supply chain and highly skilled workforce to serve the company's emerging market customers.
BiotechCorp comes under the purview of the Ministry of Science, Technology and Innovation (MOSTI). -- BERNAMA